Amgen (AMGN) Short-term Investments (2009 - 2023)

Amgen (AMGN) has reported Short-term Investments for 15 consecutive years, with $1.0 million the latest figure, recorded in Q1 2023.

• In Q1 2023, Short-term Investments fell 93.75% year-over-year to $1.0 million; the TTM figure through Mar 2023 stood at $1.0 million (down 93.75% YoY), while the FY2022 annual figure was $1.7 billion, up 3391.67% from the prior year.
• Short-term Investments came in at $1.0 million for Q1 2023 at Amgen, down from $1.7 billion in the prior quarter.
• The five-year high for Short-term Investments was $18.9 billion in Q1 2019, with the low at $1.0 million in Q1 2023.
• Average Short-term Investments over 5 years is $4.1 billion, with a median of $2.0 billion recorded in 2022.
• The largest YoY upside for Short-term Investments was 3391.67% in 2022 against a maximum downside of 99.64% in 2022.
• Year by year, Short-term Investments stood at $2.9 billion in 2019, then soared by 52.44% to $4.4 billion in 2020, then sank by 98.9% to $48.0 million in 2021, then surged by 3391.67% to $1.7 billion in 2022, then plunged by 99.94% to $1.0 million in 2023.
• According to Business Quant data, Short-term Investments over the past three periods registered $1.0 million, $1.7 billion, and $2.0 billion for Q1 2023, Q4 2022, and Q3 2022 respectively.